For 15 years, targeted therapies against BRAF (mutated in 50–60% of primary melanoma) or MEK protein has been developed, and some of them are commercialized, including BRAF inhibitors such as vemurafenib (or PLX4032), dabrafenib and encorafenib, as well as MEK inhibitors such as selumetinib, trametinib, cobimetinib or binimetinib1. This evidence concerns the gene BRAF and melanoma.